02:01 PM EDT, 05/05/2025 (MT Newswires) -- Regentis Biomaterials filed a registration statement Monday for the sale of 1 million shares via an initial public offering.

The regenerative medicine company expects to price the IPO at between $10 and $12 per share.

Shares are expected to begin trading on NYSE American under the "RGNT" ticker once approved.

The company will use proceeds from the IPO to fund research and development activities, including for lead product candidate GelrinC, which is being developed to treat knee injuries.